Compare Eli Lilly And Co (LLY) vs Ferrari NV (RACE) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.

LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.

Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock shows consistent revenue growth, reaching $7.15B in 2025, and robust profitability with a 22.25% net income margin. Recent quarterly earnings have exceeded expectations, and the company is executing a share buyback program. Technical indicators point to near-term pressure, with support at $381 and resistance at $390.

The outlook remains positive due to strong brand equity and financial performance, with a consensus price target of $462.75 implying 19% upside. Risks include high valuation multiples and exposure to economic cycles. Wall Street sentiment is bullish, with 74% of analysts rating it a Buy, supported by institutional accumulation.